An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
On Nov. 16, the ACR Convergence 2024 session Toward Personalized Medicine in Pediatric Lupus will present important recent findings in the pathophysiology of pediatric lupus. Virginia Pascual, MD, is program director of an NIAID-funded Autoimmunity Center of Excellence and a NIAMS-funded Center for Lupus Research at Weill Cornell Medical College, New York. Her laboratory is…
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
The ACR’s response to the Centers for Medicare & Medicaid Services addresses the likely harm of the proposed conversion factor on the solvency and stability of rheumatology practices. The comments also include recommendations on complex drug administration coding, inflation-adjusted drug rebates and extending telehealth flexibilities.
In the early days of the COVID-19 pandemic, confusion and concern for immunosuppressed patients grew among rheumatologists and patients alike. Research has helped bridge the knowledge gap, and treatment options for COVID-19 have helped ease concerns.
Mohammad A. Ursani, MD, FACP, RhMSUS, Iman Qaiser, MD, & Mamdouh Mahmoud, PhD |
Intermittent fasting—defined as alternating between cycles of eating and going without food over a given period of time—has become popular with individuals seeking to lose weight or balance their lifestyle in recent years. During Ramadan (a period based on the Gregorian calendar that changes from year to year), able-bodied Muslims are obligated to observe a…
Georg Schett, MD, presented the latest research into CAR T cell therapy for rheumatic diseases, such as systemic lupus erythematosus & other conditions. These findings demonstrate remarkable and durable efficacy for the treatment, as well as the potential for disease remission in some patients.
SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.